mRNA Synthesis Raw Materials Market Analysis
According to SNS Insider, the mRNA synthesis raw materials market size was valued at USD 1.70 billion in 2024 and is projected to reach USD 2.67 billion by 2032, expanding at a CAGR of 5.81% during the forecast period of 2025–2032. In parallel, the U.S. market alone accounted for USD 0.57 billion in 2024, and is forecasted to grow to USD 0.81 billion by 2032, at a CAGR of 4.62%.
The rising global focus on mRNA-based vaccine platforms and personalized medicine has accelerated the demand for high-quality synthesis raw materials, including nucleotides, plasmid DNA, enzymes, and capping agents. This demand is not only fueled by vaccine manufacturers but also by a growing number of biopharmaceutical and biotechnology companies focused on developing mRNA therapeutics for cancer, infectious diseases, and rare genetic disorders.
Get a Free Sample Report of mRNA Synthesis Raw Materials Market @ https://www.snsinsider.com/sample-request/7609
Growth Drivers
One of the primary drivers fueling the growth of the mRNA synthesis raw materials market is the surge in demand for mRNA-based therapeutics and vaccines, following the global success of mRNA COVID-19 vaccines. The adaptability of mRNA platforms for rapid vaccine development has positioned them at the forefront of next-generation biologics. With ongoing investments in R&D and expanding applications across oncology, rare diseases, and infectious diseases, the need for high-fidelity synthesis materials such as modified nucleotides (e.g., N1-methylpseudouridine-triphosphate, 5-Methylcytidine triphosphate) and clean capping reagents is growing significantly.
In addition, the expansion of contract research organizations (CROs) and contract manufacturing organizations (CMOs) has opened up new channels for high-volume mRNA synthesis and custom manufacturing, further driving the procurement of synthesis-grade raw materials. Favorable regulatory frameworks and government funding initiatives, particularly in the U.S. and Europe, are also contributing to the accelerated commercialization of mRNA technologies. As biotech startups and academic institutes continue to explore the therapeutic potential of mRNA, the market is poised for consistent growth.
Key Players in the mRNA Synthesis Raw Materials Market
Thermo Fisher Scientific
Merck KGaA
Cytiva
TriLink BioTechnologies
New England Biolabs
BioNTech
Moderna
CureVac
GenScript
ST Pharm
These companies are actively investing in expanding their raw material portfolios, optimizing GMP production processes, and forming strategic alliances to meet the rising global demand for mRNA technologies.
Market Segmentation
By Type
Capping Agents
CleanCap Reagents
ARCA (Anti-Reverse Cap Analog)
Others
Nucleotides
Modified Nucleic Acids
N1-methylpseudouridine-triphosphate
5-Methylcytidine triphosphate (5mCTP)
Others
Natural Nucleic Acids
Adenine
Guanine
Cytosine
Uracil
Plasmid DNA
Enzymes
Polymerase
RNase Inhibitor
DNase
Others
Others
By Application
Vaccine Production
Therapeutics Production
Others
By End Use
Biopharmaceutical & Pharmaceutical Companies
CROs & CMOs
Academic & Research Institutes
The biopharmaceutical & pharmaceutical segment currently dominates the market, owing to large-scale investments in mRNA vaccine development and commercialization. Meanwhile, academic and research institutions continue to explore the fundamental science and emerging applications of mRNA technology, adding to the overall demand for high-purity synthesis inputs.
Regional Outlook
North America remains the leading region in the mRNA synthesis raw materials market, largely due to robust R&D infrastructure, high healthcare expenditure, and the presence of key market players. The U.S., in particular, is a major hub for mRNA therapeutics development, bolstered by ongoing public-private partnerships and government support. Europe is expected to follow, driven by increasing collaborations among biotech companies, universities, and public health agencies. The Asia-Pacific region is witnessing a steady uptick in demand, supported by the growth of its biomanufacturing capabilities and increasing investments in genetic and molecular medicine.
Need Any Customization Research on mRNA Synthesis Raw Materials Market, Enquire Now @ https://www.snsinsider.com/enquiry/7609
Recent Developments
In 2023, Thermo Fisher Scientific expanded its mRNA synthesis capabilities by enhancing its raw material production capacity for nucleotides and enzymes, responding to increasing global demand.
In late 2024, TriLink BioTechnologies launched next-gen CleanCap analogs designed to improve the stability and translational efficiency of mRNA therapeutics.
Moderna and BioNTech both reported strategic partnerships with raw material suppliers to scale up production and ensure supply chain reliability for upcoming mRNA therapies beyond COVID-19.
As the global biotech landscape continues to evolve, the mRNA synthesis raw materials market is anticipated to play a foundational role in enabling scalable, efficient, and high-quality production of advanced biologics.
Read Our Other Report
Nanotechnology Drug Delivery Market
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
